Changes in Central Macular Thickness and Retinal Nerve Fiber Layer Thickness in Eyes with Vogt-Koyanagi-Harada Disease: A 2-Year Follow-Up Study

Ophthalmologica. 2018;239(2-3):143-150. doi: 10.1159/000481863. Epub 2018 Jan 16.

Abstract

Purpose: To investigate the central macular thickness (CMT) and retinal nerve fiber layer (RNFL) thickness in eyes with Vogt-Koyanagi-Harada (VKH) disease associated with optic disc swelling and serous retinal detachment through a 24-month follow-up period.

Methods: We prospectively investigated 28 eyes of 14 treatment-naïve patients with acute VKH disease associated with optic disc swelling and serous retinal detachment and 30 eyes of 15 normal individuals to compare changes in the CMT and average RNFL thickness.

Results: The CMT was significantly lower in the eyes of the VKH group at 12 and 24 months. The RNFL thickness was significantly higher in the eyes of the VKH group at the initial visit and at the 6- and 12-month follow-up visits, but no significant difference was found between the VKH group and control group at the 24-month follow-up visit.

Conclusion: Significant changes in the CMT and RNFL thickness in the eyes with VKH disease were observed during the 24-month follow-up period. When diagnosing or monitoring diseases including glaucoma and neuro-ophthalmic diseases that affect the retinal thickness in patients with VKH disease, we recommend considering longitudinal changes in the retinal thickness.

Keywords: Central macular thickness; Optical coherence tomography; Retinal nerve fiber layer thickness; Vogt-Koyanagi-Harada disease.

Publication types

  • Observational Study

MeSH terms

  • Disease Progression
  • Female
  • Fluorescein Angiography / methods*
  • Follow-Up Studies
  • Fundus Oculi
  • Humans
  • Macula Lutea / pathology*
  • Male
  • Middle Aged
  • Nerve Fibers / pathology*
  • Papilledema / diagnosis*
  • Papilledema / etiology
  • Prospective Studies
  • Retinal Ganglion Cells / pathology*
  • Time Factors
  • Tomography, Optical Coherence / methods*
  • Uveomeningoencephalitic Syndrome / complications
  • Uveomeningoencephalitic Syndrome / diagnosis*